Synergistic IRAK4 Degrader Systems for Enhanced Treatment of MYD88-Mutant B-Cell Lymphomas

Publication ID: 24-11857535_0008_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic IRAK4 Degrader Systems for Enhanced Treatment of MYD88-Mutant B-Cell Lymphomas,” Published Technical Disclosure No. 24-11857535_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857535_0008_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,535.

Summary of the Inventive Concept

The present inventive concept integrates IRAK4 degraders with distinct technologies, such as AI, IoT, blockchain, and nanomaterials, to create novel systems for treating MYD88-mutant B-cell lymphomas, enhancing treatment outcomes and patient care.

Background and Problem Solved

The original patent disclosed methods of treating MYD88-mutant B-cell lymphomas using IRAK4 degraders. However, these methods have limitations, including the need for more accurate patient diagnosis, optimized treatment regimens, and improved treatment efficacy. The present inventive concept addresses these limitations by combining IRAK4 degraders with synergistic technologies to create more powerful and effective treatment systems.

Detailed Description of the Inventive Concept

The inventive concept encompasses four synergistic systems: (1) an AI-driven diagnostic tool for identifying patients with MYD88 mutations, (2) a blockchain-secured genomic data platform for tracking changes in gene expression, (3) a nanomaterial-based delivery system for targeting specific lymphoma cells, and (4) an IoT-enabled wearable device for monitoring patient vital signs. These systems integrate with IRAK4 degraders to optimize treatment outcomes, improve patient care, and enhance the efficacy of MYD88-mutant B-cell lymphoma treatment.

Novelty and Inventive Step

The new claims introduce a synergistic combination of IRAK4 degraders with distinct technologies, which is not obvious from the original patent. The inventive concept's novelty lies in the integration of these technologies to create more powerful and effective treatment systems, resulting in improved treatment outcomes and patient care.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include the use of different AI algorithms, blockchain platforms, or nanomaterials. Variations may also include the integration of additional technologies, such as quantum computing or gene editing, to further enhance treatment outcomes.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the development of novel cancer treatments. The target market includes pharmaceutical companies, research institutions, and healthcare providers seeking to improve treatment outcomes for patients with MYD88-mutant B-cell lymphomas.

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Oncology, pharmaceutical biotechnology, with a specialized focus on targeted molecular therapies for B-cell lymphomas and precision medicine technologies

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced degrees in molecular biology, oncology, or pharmaceutical sciences, possessing expertise in cancer therapeutics, molecular targeting, and emerging digital health technologies

Obviousness Rationale

A PHOSITA would recognize that integrating digital technologies with targeted molecular therapies represents a predictable extension of precision medicine approaches. The combination of IRAK4 degraders with AI, blockchain, and nanomaterial technologies follows established trends in personalized cancer treatment. The proposed systems leverage known technological capabilities to enhance diagnostic, monitoring, and treatment strategies for MYD88-mutant lymphomas.

Obvious Combinations & Variations

Source Patent Element

IRAK4 degrader targeting MYD88-mutant B-cell lymphomas

PTD Variation

AI-driven diagnostic tool for identifying patients with MYD88 mutations

Obviousness Reasoning

Precision medicine increasingly relies on targeted diagnostic technologies to stratify patient populations, making this combination a predictable application of known techniques in personalized oncology

Source Patent Element

Specific dosing strategies for IRAK4 degraders

PTD Variation

Blockchain-secured genomic data platform for tracking treatment response

Obviousness Reasoning

Data tracking and secure management of patient genomic information is a standard approach in modern clinical research, representing an obvious extension of existing treatment monitoring techniques

Source Patent Element

Molecular targeting of lymphoma cells

PTD Variation

Nanomaterial-based delivery system for enhanced targeting of specific lymphoma cells

Obviousness Reasoning

Nanomaterial drug delivery represents a well-established approach in pharmaceutical sciences for improving targeted drug delivery and reducing systemic toxicity

Source Patent Element

Treatment method for MYD88-mutant B-cell lymphomas

PTD Variation

IoT-enabled wearable device for monitoring patient vital signs and treatment response

Obviousness Reasoning

Remote patient monitoring is a known technique in modern healthcare, with predictable applications in tracking cancer treatment outcomes

Source Patent Element

Molecular targeting of IRAK4 in lymphoma treatment

PTD Variation

Quantum computing simulation of molecular interactions to identify novel IRAK4 degraders

Obviousness Reasoning

Advanced computational methods for drug discovery are a standard approach in pharmaceutical research, representing an obvious extension of existing molecular screening techniques

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857535 and the present published technical disclosure, a person of ordinary skill in the art would find the proposed technological integrations and treatment methodologies obvious, as they represent predictable combinations of known techniques in precision oncology and digital health technologies, thereby rendering potential claims to such systems anticipated or obvious under 35 U.S.C. § 103.

Original Patent Information

Patent Number	US 11,857,535
Title	Methods of treating mutant lymphomas
Assignee(s)	Kymera Therapeutics, Inc.